Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT05263947 2026-02-24

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Phase 2 Completed

35 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

12 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07416058 2026-02-17

PHOENIX

61 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07398599 2026-02-10

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Phase NA Recruiting

30 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT03896074 2026-02-09

BEAT

206 enrolled

Phase 2 Active not recruiting

Non-small-cell Lung Cancer Patients

NCT04958811 2026-01-26

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

29 enrolled

Lung Neoplasms

NCT07244926 2025-11-24

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

31 enrolled

Phase 2 Active not recruiting

Lung Neoplasms

NCT05781308 2025-11-18

ADAPTABLE

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05588388 2025-11-17

BELIEVE

Phase 2 Recruiting

39 enrolled

Small Cell Lung Carcinoma

NCT07182708 2025-09-19

HOFIBREN

62 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

5 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

77 enrolled

NSCLC

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07083375 2025-07-24

QL1706

56 enrolled

Extensive Small Cell Lung Cancer

NCT06953843 2025-07-14

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Phase 2 Recruiting

366 enrolled

NSCLC Stage IV Without EGFR/ALK Mutation

NCT07014215 2025-06-10

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04042558 2025-05-31

GFPC 06-2018

Phase 2 Completed

150 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Phase 1 Recruiting

214 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Phase 2 Recruiting

25 enrolled

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04512430 2025-04-02

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

Phase 2 Terminated

4 enrolled 9 charts